Table 4.
PFS by Treatment Arm and Change in Circulating Tumor Cell (CTC) Levels from Baseline in the Main Analysis of ≥1 CTC
| Treatment | CTC Group | n (%) | Median PFS, Months |
|---|---|---|---|
| nab-P/C | Group 1 (+ + +) | 4 (8.9) | NE |
| Group 2 (+ ± ±) | 27 (60.0) | 8.94 | |
| Group 3 (−) | 14 (31.1) | 4.37 | |
| nab-P/G | Group 1 (+ + +) | 11 (28.2) | 4.24 |
| Group 2 (+ ± ±) | 11 (28.2) | 7.92 | |
| Group 3 (−) | 17 (43.6) | 8.75 | |
| G/C | Group 1 (+ + +) | 9 (21.4) | 3.52 |
| Group 2 (+ ± ±) | 16 (38.1) | 8.52 | |
| Group 3 (−) | 17 (40.5) | 5.65 |
Abbreviations: C, carboplatin; CTC, circulating tumor cell; G, gemcitabine; nab-P, nab-paclitaxel; NE, not evaluable; PFS, progression-free survival.